-
Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation.
Wright A, Wright D, Syngelaki A, Georgantis A, Nicolaides KH.
Am J Obstet Gynecol 2019;220:197.e1-197.e11. pdf -
The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D'Alton M, Berghella V, Nicolaides KH, Hod M.
Int J Gynaecol Obstet 2019;Suppl 1:1-33. pdf -
Predictive performance of the competing risk model in screening for preeclampsia.
Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH.
Am J Obstet Gynecol 2019;220:199.e1-199.e13. pdf -
Impaired placental perfusion and major fetal cardiac defects.
Fantasia I, Andrade W, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;53:68-72. pdf -
Good clinical practice advice: First trimester screening and prevention of pre-eclampsia in singleton pregnancy.
FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine.
Int J Gynaecol Obstet 2019;144:325-329. pdf -
First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment.
de Sousa MJR, Ribeiro R, Syngelaki A, Nicolaides KH.
Clin Rheumatol 2019;38:1251-1255. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf